Pharmaceutical compositions for dehydration, atrophy and removal of abnormal tissues
 Method (versions) and preparation for modification of eating behaviour / 2519748Group of inventions relates to medicine and can be used for modification of eating behaviour in a subject. For this purpose peripheral introduction of PYY in an amount, efficient for achieving physiological levels of PYY3-36 in blood, plasma and serum, determined after food intake, is performed; or performed is peripheral introduction of PYY agonist in an amount, efficient for imitation of physiological levels of PYY3-36 in blood, plasma or serum, determined after food intake with modification of eating behaviour, by reducing intake of calories, food consumption or appetite reduction or increase of energy consumption in the subject. Also claimed is application of PYY or its agonist as an active ingredient in production of medication. |
 Preparation for involving originating from bone marrow pluripotent stem cell into peripheral blood flow / 2519714Invention relates to chemical-pharmaceutical industry and represents a preparation for involving a mesenchymal stem cell of the bone marrow into peripheral blood from the bone marrow, which is introduced into the blood vessel or muscle and which contains any of components: (a) protein HMGB1; (b) HMGB1 protein-secreting cell; (c) a vector, into which HMGB1 protein-coding DNA is inserted; (d) protein HMGB2; (e) HMGB2 protein-secreting cell; (f) a vector, into which HMGB2 protein-coding DNA is inserted; (g) protein HMGB3; (h) HMGB3 protein-secreting cell; and (i) a vector, into which HMGB3 protein-coding DNA is inserted. |
 Method for reducing eosinophil count / 2519227Invention refers to medicine, namely immunology, and may be used for reducing eosinophil count in a human body. That is ensured by the parenteral administration of approximately 0.01 mg/kg to approximately 0.25 mg/kg of a monoclonal chimeric humanised antibody or a human antibody which binds to IL-5P and contains an immunoglobulin Fc fragment and is fucose-free; the administered antibody reduces the peripheral blood circulating eosinophil count below the detection threshold, and the circulating eosinophil calculation level remains below the detection threshold for approximately 28 days after antibody dosing. |
![Medication, inhibiting na+/h+-exchange, and halogenides of 1-dialkylaminoethyl-3-[substituted(disubstituted)phenacyl]-2-aminobenzimidazolium](http://img.russianpatents.com/img_data/1026/10268010-s.gif) Medication, inhibiting na+/h+-exchange, and halogenides of 1-dialkylaminoethyl-3-[substituted(disubstituted)phenacyl]-2-aminobenzimidazolium / 2518741Invention relates to field of pharmacology and medicine and deals with application of halogenides of 1,3-disubstituted 2-aminobenzimidazolium, of general formula I as inhibitors of Na+/H+-exchange, as well as novel 1,3-disubstituted halogenides of 2- aminobenzimidazolium. |
 Isolated polypeptide and using it for treating malignant disease and stimulating immune system, pharmaceutical composition containing such polypeptide and method of treating cancer / 2518236Invention refers to biotechnology and concerns an isolated polypeptide, a pharmaceutical composition containing such polypeptide, as well as a method of treating cancer. The presented polypeptide contains an amino acid sequence corresponding to SEQ. ID. NO: 2 or SEQ ID NO: 4. There are also characterised fragments or versions of the presented polypeptide. |
 Novel bicyclic heterocyclic compound / 2518073Claimed invention relates to novel compound of formula (1) or its pharmaceutically acceptable salt, possessing SNS inhibiting properties. In general formula |
 Prolyl hydroxylase inhibitors / 2518071Invention relates to compound of formula |
|
Method for choosing management of pregnant women with placental insufficiency and foetal growth inhibition syndrome / 2517374 Blood is examined for angiogenic factors, namely soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF). An angiogenic factor (Ka) is calculated by formula: Ka=sFlt-1/PlGF×10. If Ka is 10 or less, the pregnant woman is stated to require no admission to hospital, no case follow-up; doctor's appointments are scheduled. If Ka falls within the range of 10 to 50, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed; an amniotic fluid index (AFI) is calculated; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 10 days. The amount of infusion makes 400 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control ultrasonography, Doppler monitoring, foetal monitoring, AFI and Ka measurements are performed 2 weeks later. The pregnant woman is discharged from hospital if observing no negative trends. If Ka falls within the range of 50 to 100, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days The amount of infusion makes 800 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control Doppler monitoring and foetal monitoring are performed every 3 days; 2 weeks later control Ka is measured. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 100 or more, but less than 150, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days. The amount of infusion makes not less than 800 ml a day with the same preparations prescribed. Those are added with the preparations for homeostasis correction, including Fraxiparine, Fragmin, Clexane optionally. Control Doppler monitoring and foetal monitoring are daily. Hypamnion also requires measuring control AFI. If a gestational age is less than 34 weeks, respiratory distress syndrome (RDS) should be prevented by administering the preparation Dexon 24 mg according to the schedule: 6 mg every 12 hours 4 times. Control Ka is necessarily measured after 2 weeks of the treatment. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 150 or more, and the gestational age is more than 34 weeks, the therapeutic approach is the same, as for Ka being within 100 to 150, control Doppler monitoring, foetal monitoring are performed twice a day, as well as measuring AFI. If observing no foetal weight gain for 2 weeks of the therapy or the functional state of the foetus deteriorates, a Cesarean section is performed. If the gestational age is 34-36 weeks, the therapeutic approach and follow-up are the same as for the gestational age of 34 weeks, except for the prevention of foetal RDS. However, if observing the deterioration of a foetal movement pattern or the functional status of the foetus, a Cesarean section is performed according to the foetal monitoring and Doppler monitoring findings. If the gestational age is more than 36 weeks, and Ka is 150 or more, pre-mature delivery is applied. |
|
Agent for preventing chronic fatigue syndrome in males / 2517217 Invention refers to pharmaceutical industry, namely to an agent for preventing chronic fatigue syndrome in males. The agent for preventing chronic fatigue syndrome in males is presented in the form of suppositories containing male red deer's blood plasma, dry sweetvetch extract, L-arginine and additives in certain proportions. |
|
Method of preventing acute postoperative pancreatitis / 2517210 Invention relates to medicine and is intended for prevention of acute postoperative pancreatitis. Basic therapy is carried out, additionally prescribed are mexidol and sandostatine. Mexidol is introduced in a dose 300 mg intravenously by drop infusion an hour before the operation and in a dose 300 mg 2 times per day on the following 3 days after the operation. Sandostatine is introduced in case of the operation on pancreas in a dose 100 mcg subcutaneously 2 hours before the operation, and on the following 3 days after the operation subcutaneously in a dose 100 mcg 3 times. In case of operations on the organs of the abdominal cavity, anatomically adjacent to pancreas it is introduced in a dose 100 mcg subcutaneously 2 hours before the operation, and on the following 3 days after the operation subcutaneously in a dose 100 mcg 2 times. In case of operations on the organs of the abdominal cavity, which are not anatomically connected with pancreas it is introduced in a dose 100 mcg per day subcutaneously 2 hours before the operation, and on the following 3 days after the operation subcutaneously in a dose 100 mcg 1 time. |
|
Hydroxylated pyrimidyl cyclopentane as proteinkinase (act) inhibitor / 2520735 Invention relates to a novel compound, corresponding to formula I, and its pharmaceutically acceptable salts, possessing properties of a proteinkinase ACT inhibitor. The invention also relates to a pharmaceutical composition, containing efficient amount of the said compound, and a set for treatment of pathological state, mediated by proteinkinase ACT, which includes: a) one pharmaceutical composition, containing the compound by i.1 and b) an instruction for its application. Formula I compound corresponds to the structural formula: |
|
Method of treating spinal malignant tumours and spinal metastases of tumours / 2520682 Invention refers to medicine, namely to oncology and radiotherapy, and may be used for treating patients with spinal malignant tumours and spinal metastases of tumours accompanied by anticipated or complicated spinal disorders. That is ensured by introducing bone cement into the tumour growth centres. The bone cement formulation is specified so that its polymerisation is accompanied by generating heat sufficient to provide thermal sensibilisation of the tumour cells, and β- and γ-radionuclides are added to the cement. |
|
Using opioids or opioid mimetics for treating patients with persistent malignant tumour / 2520636 Invention refers to medicine, namely to oncology, and concerns using opioids for treating patients suffering from persistent malignant tumour. That is ensured by administering drugs containing opioids able to inhibit malignant cell proliferation in the effective amounts. |
|
Composition for preventing or treating malignant new growth containing active ingredient presented by herbal stem cell line recovered from cambium of panax ginseng, including wild ginseng or ginseng / 2520625 Invention refers to a composition for treating a malignant new growth, as well as for improving health condition in the malignant new growth. The pharmaceutical composition for treating the malignant new growth which contains one or more substances specified in a group consisting of a cell line, its extract and its culture medium, wherein the cell line is recovered from cambium of Panax ginseng. A functional foodstuff for improving health condition in the malignant new growth. |
 Method for stimulating cytotoxic immune response to tumour cells of mammary adenocarcinoma expressing specific antigens, with use of dendrite cells transfected by polyepitope dna construct / 2520091Invention refers to immunology, medicine and biotechnology. What is presented is a method for stimulating a specific anti-tumour immune response to breast cancer cells with the use of dendritic cells transfected by polyepitope DNA construct. The cells recovered from the peripheral blood of relatively healthy donors, transfected by the polyepitope structure are cultured with a non-adherent fraction of mononuclear cells. |
 Antibodies to ox-2/cd200 and their application / 2520088Claimed invention relates to immunology and biotechnology. Claimed are: a pharmaceutical composition and a method, based on an introduction to a patient of a therapeutically efficient amount of an antibody against CD200, which contains G2/G4 constant region, for treatment of the patient with malignant neoplasm, containing CD200 positive malignant cells. The said antibody against CD200 inhibits interaction between CD200 and CD200R. |
 Low-molecular inhibitors of n-terminus activation of androgen receptor / 2519948Invention relates to low-molecular inhibitors of N-terminus activation of androgen receptors of formula B: |
 Method of photodynamic therapy of tumours / 2519936Method involves using a photosensitiser (PS) pre-detected in the tumour by its fluorescence that is followed by tumour irradiation by light emission at a wave length in the spectral range of PS peak absorption. The PS is presented by the genetically coded protein KillerRed by providing its tumour expression by gene insertion into the tumour cells. The tumour is exposed to the light emission at energy density of 180-270 J/cm2 3 times every second day or 7 times daily. The protein KillerRed is preferentially localised either in mytochondria and nuclei, or in nuclei. |
 Method for immune therapy of oncological diseases and pharmaceutical compositions of sendai virus of cancer / 2519763Composition containing an isolated native biologically active Sendai virus strain deposited in the American Type Culture Collection (ATCC) No. PTA-13024, and a pharmaceutically acceptable carrier, is administered into a patient. A group of inventions also refers to a pharmaceutical composition containing the isolated, genetically engineered, biologically active Sendai virus strain prepared on the basis of a viral material deposited in the American Type Culture Collection (ATCC) No. PTA-13024. |
 Method of treating multiple myeloma / 2519750Invention relates to the field of medicine, namely to therapy and pharmacology. A therapeutically efficient amount of the substance PM00104 or its pharmaceutically acceptable salt is introduced to a mammal, in particular a human being. PM00104 or its pharmaceutically acceptable salt is introduced in a combination with medications, representing antimyeloma medications. |
|
Method of treating superficial thermal burns / 2519102 Affected areas of skin are coated with dressings impregnated with therapeutic preparations containing 1.0-2.0% hypromellose, an antiseptic specified in a group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron and 2% lidocaine hydrochloride. At the stage of wound exudation on the second or third post-injury day, the dressings impregnated with 2.0% hypromellose, the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron, and 2% lidocaine hydrochloride are used and changed once a day. At the stage of proliferation, the dressings impregnated with 1.0% hypromellose and the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron are used and changed every 2 days. At the stage of epithelisation, the dressings impregnated with 1.0% hypromellose and the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron are used and changed every 3 days until the wound surface is completely epithelised. |
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues, and to using it. The pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues contains a composite of an inorganic polymer iron salt as an active ingredient; the composite of the inorganic polymer iron salt is polymer ferrous sulphate silicate (PFSS), or polyferrous silicate chloride (PFSC), or polyphosphate ferrous sulphate (PPFS). Using the pharmaceutical composition consists in preparing the drug for dehydration, atrophy and removal of abnormal tissues.
EFFECT: pharmaceutical composition is effective for dehydration, atrophy and removal of abnormal tissues in treating haemorrhoids, haemangiomas, varicose veins, burns, bleeding traumatic wounds, local wounds caused by chemicals or microorganisms.
9 cl, 12 dwg, 2 tbl, 7 ex
The SCOPE of the INVENTION
The present invention relates to pharmaceutical compositions for dehydration, atrophy and removal of pathological tissues in the medical field.
BACKGROUND of the INVENTION
Polyglutamyl sulfate (PFS) is a polymer obtained from the primary ferrous sulfate salt, this compound has the molecular formula of Fe4(OH)2(SO4)5. Molecular formula polizeiskogo sulfate [Fe2(OH)n(SO4)3-n/2]m, where 0.5<n<1 and m=f(n).
Usually polyglutamyl sulfate is used as the inorganic coagulant. When compared with other coagulants, polizeiskogo sulfate has several advantages, such as relatively low dosage, adapted for use in a wide range of pH, a high rate of removal of particles (turbidity, chemical oxygen consumption (COD), suspended solids etc), low concentration of precipitation, high coagulation rate, good decolorizing effect, etc. currently polyglutamyl sulfate is widely used for industrial wastewater treatment, municipal sewage and domestic wastewater. When hydrolysis occurs polizeiskogo sulfate in water, it forms a multicore hydroxyl complex, which has a strong adsorption to colloidchemical in various water environments what causes aggregation and coagulation by binding, bypass and formation of cross-links. In recent years, based coagulants such as polysilicate and polyglutamyl sulfate, researchers have developed a new inorganic and organic polymeric composition coagulants containing polymer composites ferrous salts: primerselect composites of iron salts, such as polyglutamyl silicate chloride (PFSC), polyglutamyl sulfate silicate (PFSS) and the polysilicate glandular alumalite (PAFSC); polyphosphate glandular composite salts such as polyphosphate, ferrous sulfate (PPFS); polyaluminosilicate composite salts such as polymer alumosilicates phosphate (PAFP); coagulants containing polyglutamyl chloride sulfate (PFCS); coagulants containing copolymers glandular salts, such as semi-aluminum ferric chloride (PAFC), organic polymeric coagulants, such as organic cationic polymer coagulants-DMC copolymer, a strong natural cationic polymer CTS-AM-DMC (chitosan(S)-methacryloyl-oxyethyl-triethyl ammonium chloride(D)-acrylamide (AM) strong cationic natural polymer), coagulants and the like; organic/inorganic polymer composite coagulants, such as CAF (composite polymeric organic/inorganic coagulants, consisting of Fazana, polyaluminum and ferric chloride), and their analogues.
Compared with ferrous sulfate and iron polysulfate (PFS), the above types of coagulants are large molecular weight, the stronger the adsorption and the formation of relationships, a better ability to remove suspended solids, COD, biologically consumed oxygen demand (BOD).
For example, when processing the sewer drain dosage of polyphosphate, ferrous sulfate, silicate (PFSS) one-third less than polizeiskogo sulfate. It was noted that the treatment of the slurry of coal dosage of inorganic coagulant semi-aluminum chloride exceed 1 kg per ton of coal, if used independently, and the dosage of organic coagulant, polyacrylamide slightly less than 0.1 kg per ton of coal, if you apply yourself. However, if a joint application, the dosage is significantly less thanks to their joint use.
Although the use of the above substances as coagulants is well known, to date, no one has tried to use the properties of these substances for medical purposes. This means that the pathological tissue in living organisms dehydrate, atrophy and, ultimately, discarded. There is therefore a need to create an unknown pharmaceutical composition for dehydration, Trofimovna removal of pathological tissues.
The INVENTION
The present invention is to provide a new effective pharmaceutical composition for dehydration, Trofimovna and removal of pathological tissues.
In the course of their medical practice, the inventors surprisingly found that when using composite inorganic ferrous salt as a coagulant and/or composite polymer inorganic ferrous salt as a coagulant for medical purposes, these substances cause dehydration, atrophy and subsequent removal of pathological tissues. For example, the use of polizeiskogo sulfate, polymeric ferric sulfate silicate (PFSS), polizeiskogo silicate chloride (PFSC) and polyphosphate ferrous sulfate (PPFS) will lead to the fact that the pathological tissues of the human body affected by local processes or wounds, dehydrated, atrophy and, in the end, are removed. These types of coagulants can be used in medical practice for the treatment of hemorrhoids, hemangiomas, varices, Wagram, abscesses, tumors, burn wounds, traumatic wounds bleeding and/or local damage caused by chemical substances or microorganisms, with the aim of dehydration, atrophy and removal of pathological tissues, which will lead to cure of the patient. The developers of this is subramania found when using coagulants such as ferric sulfate for treatment of bleeding wounds to stop bleeding, formed the black dense substance in the form of precipitation, clean and transparent substance was separated. The developers have determined that the mechanism of this phenomenon was dehydration, atrophy and destruction of the blood and blood tissue, and not widely known from the literature, the mechanism of bleeding in Montello (Monsell), when bleeding is caused by clots from platelets and fibrino, aggregation of erythrocytes and accelerated coagulation of blood.
In medicine, many diseases are caused by pathological changes in the local tissue. Diseases such as hemorrhoids, hemangioma (hemangioma in or on the skin, anus, liver, brain etc), varicose lower extremities, intracranial hematoma, lymphangioma, hygroma, abscesses, some types of malignant tumors, burn wounds, traumatic bleeding wounds and/or local wound damage caused by chemicals or microorganisms, etc. Symptoms of these diseases are abnormal tissue growth, it's congestion, hyperemia, hemorrhage, edema, inflammation, exudation and necrosis pathological tissues, which are abnormal and infected biological colloidal solution, the origin is s on drains household or industrial objects.
Therefore, the present invention is a pharmaceutical composition for dehydration, atrophy and removal of pathological tissues, consisting of polymer inorganic ferrous salts and/or inorganic polymer composite ferrous salt as active ingredients. Polymer inorganic ferrous salt is polyglutamyl sulfate, and the inorganic polymer composite ferrous salt is selected from the group consisting of ferrous salts polysilicate, polyphosphate ferrous salts and their analogues.
In the pharmaceutical compositions of the selection polyphosphate ferrous salts is given policlasista sulfate silicate (PFSS) and/or policlasista silicate chloride (PFSC), and polyphosphate ferrous salts are polyphosphate ferrous sulphate (PPFS).
The manufacture of pharmaceutical compositions according to this invention is carried out in the form of powder, paste, powder for injection, liniment for external application, suppozitornyj form or in the form of sprays.
The pharmaceutical composition according to this invention is composed of an anesthetic substance, in particular local anesthetics. For example, the pharmaceutical composition of this invention contains one or more anesthetics selected from the group consisting of liubomirova the ain ropivacaine, lidocaine hydrochloride, menthol, methylene blue, procaine and tetracaine.
In one embodiment of the present invention the pharmaceutical composition is a powder consisting of 1-60 wt.%, preferably 5-60 wt.%, more preferably 10-50 wt.% polymer inorganic ferrous salts and/or inorganic polymer composite ferrous salt, the necessary quantity of anesthetic, and a balanced amount of pharmaceutically acceptable solid filler.
In another embodiment of the present invention the pharmaceutical composition is a powder form, consisting of 1-60 wt.%, preferably 5-60 wt.%, more preferably 10-50 wt.% polymer inorganic ferrous salts and/or inorganic polymer composite ferrous salt, 40-80 wt.% zeolite powder and the required balance amount of another pharmaceutically acceptable solid filler.
In another embodiment of the present invention the pharmaceutical composition is a paste-like form consisting of 1-60 wt.%, preferably 5-60 wt.%, more preferably 10-50 wt.%, consisting of 1-60 wt.%, preferably 5-60 wt.%, more preferably 10-50 wt.% polymer inorganic ferrous salts and/or inorganic polymer composite ferrous salt, a sufficient amount of anesthetic, and rebueno balance amount of pharmaceutically acceptable excipient.
In another embodiment of the present invention the pharmaceutical composition is an aqueous solution consisting of 0.2 to 60 wt.%, preferably 1-60 wt.%, more preferably 5-60 wt.% polymer inorganic ferrous salts and/or inorganic polymer composite ferrous salt, the necessary quantity of anesthetic, and the desired balance amount of water. For example, the pharmaceutical composition according to this invention, may be made initially in the form of powder for injection, and then transferred in the form of an aqueous solution with a concentration of more than 0.2% for local injection in the pathological tissue in clinical use.
As another aspect of the present invention, it provides an opportunity to use the above-mentioned pharmaceutical composition for the production of drugs designed for dewatering, atrophy and removal of pathological tissues. For example, it is used for the production of drugs for the treatment of diseases such as hemorrhoids, hemangioma (hemangioma in or on the skin, anus, liver, brain etc), varicose lower extremities, intracranial hematoma, lymphangioma, hygroma, abscesses, some types of malignant tumors, burn wounds, traumatic bleeding wounds and/or local wound damage caused by chemicals or microorganisms.
the Developers of the present invention used polymer inorganic ferrous salt and/or inorganic polymer composite ferrous salt, which has traditionally been used as reagents for water treatment, for the treatment of pathological tissue for dehydration and atrophy. The thus treated fabric is then absorbed or rejected normal tissues. The effects of suppression of pathological tissues pharmaceutical composition of the present invention is completely amazing. The pharmaceutical composition of the present invention has a good price-quality, easy to use and has a significant effect in the treatment of such vascular diseases as hemorrhoids, hemangioma, hematoma (including hematoma caused by cerebral hemorrhage, blood clots and varicose lower extremities and local trauma such as bleeding and swelling. The composition has the property to kill cells of various malignant tumors with targeted injection.
The present invention will be explained in detail in the following examples. Based on the first opening of the medical use of polymer inorganic ferrous salts and/or inorganic polymer ferrous salt composite, the present invention is not limited to the forms of cooking and the ratio of ingredients given in the above examples. Any pharmaceutical composition containing inorganic polymer glandular with the ü and/or composite polymer inorganic ferrous salt as an active component for dehydration and atrophy pathological tissues in the medical field, or the use of such compositions is the protection scope of the present invention.
A BRIEF DESCRIPTION of the ACCOMPANYING ILLUSTRATIONS
Figure 1-12 are photographs of different patients, made to demonstrate the medical effects of the pharmaceutical compositions according to this invention.
PREFERRED VARIANTS of the PRESENT INVENTION
Experiments in vitro
The authors of the present invention used polymer inorganic ferrous salt, i.e. polyglutamyl sulfate, which has a larger molecular weight than ferrous sulfate, for experiments in vitro with different samples of human blood, i.e. not coagulated blood without anticoagulants, not coagulated blood with anticoagulants and naturally coagulated blood. Experiments have shown that all types of blood precipitate and dehydrate without exception.
Based on the conducted experiments, the ratio for the reaction is 2 ml of human blood to 0.4 ml of 10 wt.% solution polizeiskogo sulfate. These data can be taken as the amount of activity polizeiskogo sulfate, which means that the relative concentration or dosage to obtain an equivalent effect. For a more secure and advantageous use of the invention the authors recommended volume with the relationship 5 wt.% polizeiskogo sulfate to pathological tissues such as 1:3. In the same way in vitro experiments can be defined activity for dehydration and atrophy pathological tissues pharmaceutical compositions of the present invention, and suitable options for clinical use can be determined by experiments.
The following tables summarize the procedures and results of in vitro experiments on the application of polizeiskogo sulfate. Table 1 shows the in-vitro experiments using polizeiskogo sulfate for dewatering of human blood and the corresponding results. Table 2 shows the in vitro reaction polizeiskogo sulfate at low concentrations with human blood, i.e. dehydration.
| Table 2 | ||
| In vitro experiments with low concentrations polizeiskogo sulfate | ||
| Group | 1 | 2 | 3 |
| Content | 0.2 ml of 5% polizeiskogo sulfate and 2 ml of human blood (1:10) | 0.4 ml of 5% polizeiskogo sulfate and 2 ml of human blood (1:5) | 1 ml clotted forehead is aceskay blood and 0.2 ml of 5% polizeiskogo sulfate |
| Results 1 24 hour | A significant amount of black sludge and water is observed after 2 min; the Reaction was completed after 20 min; the precipitate of red blood color (++) (surveillance 24 hours) | A significant amount of black sludge and water is observed after 2 min; the Reaction was completed after 20 min; the precipitate of red blood color (++) (surveillance 24 hours) | A significant amount of black sludge and water is observed after 2 min; the Reaction was completed after 20 min; the precipitate of red blood color (++) (surveillance 24 hours) |
| Results 2 48 hours | Sediment the red blood color (+); not quite a coiled | Sediment the red blood color (+-); not quite a coiled | Sediment the red blood color (+-); not quite a coiled |
| Results 3 72 hours | Same as above | Sediment the red blood color (+-); not quite a coiled | Same as above |
| Conclusions | Weak reaction | The reaction close to completion, 5% polyglutamyl sulfate recommend the tsya as safe and optimal connection; the recommended clinical dosage is 1:3 | 1. Same as left; 2. Clotted blood can dissolve |
During the experiments, the authors observed that the polymer inorganic ferrous salts such as polyglutamyl sulfate and inorganic polymer composite ferrous salt (PFSS), polyglutamyl silicate chloride (PFSC) and polyphosphate, ferrous sulfate (PPFS), showed a high coagulating and dewatering ability in relation to human blood, whereas polymeric aluminum salt, such as polyaluminium chloride and polyaluminium sulfate, and organic polymer coagulant, as polyacrylamide, did not show the ability to dehydration human blood. If you mix these two substances, the dewatering properties of polymer inorganic ferrous salts will decrease or disappear altogether.
Preparation and use of pharmaceutical combinations
Example 1
10 grams polizeiskogo sulfate dissolved in 90 grams of distilled water. The resulting solution was placed in ampoules of 3 ml, free from bacteria, cleaned and sealed. Dilute the resulting solution an equal volume consisting of 1.5 wt.% levobupivacaine and 1 wt.% methylene blue, and get the medicine for injection, consisting of 5 wt.% polizeiskogo sulfate, 0.75 wt.% the lion is of bupivacaine and 0.5 wt.% methylene blue. To treat this part of various hemorrhoids, hemangioma, varicose lower limbs in the required doses.
The procedure of injection requires stages of cleaning and sterilization of the places subjected to the procedure; the introduction of the solution into the hemorrhoids, hemangioma, hematoma, or blood clots in several points; after that you must press this place swab in order to fully distribute the solution inside the injection area, as the solution becomes frozen within seconds. Hematoma and hemangiomas begin to soften, being dehydrated to atrophy and disappear in three minutes or more. The processes of dehydration and atrophy finish from ten to twenty minutes. After seven to fourteen days of pathological tissue or replaced by normal tissues, or rejected, and wounds are healed. No side effects, bleeding, scarring or scarring was not observed. Therefore, this method is a new dewatering therapy for the treatment of hemorrhoids, hemangiomas, bruising and blood clots. Pharmaceutical compositions are very specific, fast and excellent effect dehydration and Trofimovna pathological tissues with blood stagnation caused by varicose, a blood clot in the hemorrhoid nodes that were not detected anywhere in the world literature.
Example 2
7 g of polymer glandular with lift silicate dissolved in 93 g of distilled water and then dispensed into sterile ampoules of 3 ml, pull vacuum and sealed. Dilute it (the contents of the ampoule) an equal volume of injecting a mixture containing 1.5 wt.% levobupivacaine and 1 wt.% methylene blue, and get the composition for injection containing 3.5 wt.% polymer, ferrous sulfate, silicate, 0.75 wt.% levobupivacaine and 0.5 wt.% methylene blue. Apply in sufficient volume to treat hemorrhoids, hemangiomas, varicose veins, bruising and bleeding.
Example 3
7 g polizeiskogo silicate chloride dissolved in 93 g of distilled water and then dispensed into sterile ampoules of 3 ml, pump out air and sealed. Dilute it (the contents of the ampoule) an equal volume of injecting a mixture containing 1.5 wt.% levobupivacaine and 1 wt.% methylene blue, and get the composition for injection containing 3.5 wt.% polizeiskogo silicate chloride, 0.75 wt.% levobupivacaine and 0.5 wt.% methylene blue. Apply in sufficient volume to treat hemorrhoids, hemangiomas, varicose veins, bruising and bleeding.
Example 4
7 g of polyphosphate ferrous sulfate dissolved in 93 g of distilled water, and then dispensed into sterile ampoules of 3 ml, pump out air and sealed. Dilute it (the contents of the ampoule) an equal volume of injecting a mixture containing 1.5 wt.% levobupivacaine and 1 wt.% met the Lenovo blue, and get the composition for injection containing 3.5 wt.% polyphosphate ferrous sulfate, 0.75 wt.% levobupivacaine and 0.5 wt.% methylene blue. Apply in sufficient volume to treat hemorrhoids, hemangiomas, varicose veins, bruising and bleeding.
Example 5
10 grams of powder polizeiskogo sulfate mixed with 90 grams of paraffin oil, 1 gram of menthol and 0.75 grams of levobupivacaine before the formation of a soft paste. Soft paste is placed in plastic tubes of 10 grams in a tube and sealed for clinical use. Apply a soft paste on traumatic wounds, burns, local damage caused by chemical substances or cytotoxins, wounds infected with bacteria or viruses, or to remove purulent sputum after removal of pus. This treatment can give the effect of purification, removal of pus, destruction of bacteria and viruses, disinfection, create an impervious seal, drainage, education films and extended treatment.
Example 6
10 grams of powder polizeiskogo sulfate, 0.25 gram of menthol and 0.75 gram of levobupivacaine dissolved in 90 grams of distilled water, passed through bacterial filter, placed in a sterile bottle made of dark glass or plastic bottles of 100 ml, 250 ml or 500 ml and pack the La clinical use. Apply for the treatment of traumatic wounds, infected and inflamed wounds, or removal of purulent sputum after removal of pus, and local wounds caused by chemical substances or cytotoxins, by applying to the wound or rubbing. This treatment can give the effect of purification, removal of pus, destruction of bacteria and viruses, disinfection, create an impervious seal, drainage, education films and extended treatment.
Example 7
5 grams of powder polizeiskogo sulfate, 0.25 gram of menthol or mint, 0.75 gram of levobupivacaine dissolved in 94 grams of distilled water, passed through bacterial filter, placed in a sterile bottle made of dark glass or plastic bottles of 100 ml, 250 ml or 500 ml and pack for clinical use. Apply for the treatment of traumatic wounds, infected and inflamed wounds, or removal of purulent sputum after removal of pus, and local wounds caused by chemical substances or cytotoxins, by applying to the wound or rubbing. This treatment can give the effect of purification, removal of pus, destruction of bacteria and viruses, disinfection, create an impervious seal, drainage, education films and extended treatment.
These clinical observations
Glandular subsulfate, reorganizes the I polymer ferrous salt (polyglutamyl sulfate) and the composite polymer inorganic ferrous salt (polymer, ferrous sulfate, silicate) has been successfully used in the clinic for the treatment of relevant diseases.
Clinical experiment I
A saturated solution of ferrous subsulfate containing 0.5 wt.% poison frogs, deposited on the surface 136 of cancer, located on the face, body, hands and feet of a patient suffering from senile angioma. Then the solution was administered by injection into the body of the tumor with a needle. Tissue structures and blood in these tumors was solid and coagulate. Body tumors were then magcalas, was dehydrated and atrophied with scab formation. It took 10 to 20 seconds for a single nodule, thus all tumors can be removed by two doctors for one hour. The scabs fall off within 7-10 days.
Clinical experiment II
0.25 ml of 5% polizeiskogo sulfate were introduced to a patient suffering from a venous expansion in the anal canal (also known as external hemorrhoids) by external injection. Pathological blood vessel hardened to stone state for a few seconds, then 1 minute to soften. The blood vessel was dehydrated and atrophied, then became flat for 12 minutes.
Clinical experiment III
Polyglutamyl sulfate and polymer, ferrous sulfate, silicate, was used as the composition for dehydration, atrophy and removal of pathological tissues from 130 patients suffering the surrounding diseases, including hemorrhoids, varicose, angiomas and cancerous growths. Hemorrhoids included peripheral mixed hemorrhoids, internal hemorrhoids and external hemorrhoids. Peripheral mixed hemorrhoids were, in most cases, acute incarcerated hemorrhoids with symptoms varying degrees of infection, bleeding (drops or seepage), thrombosis, necrosis, suppuration, aversion to cold, fever, sharp pain, etc. Among these patients, some of them suffered from varicose internal and external hemorrhoids. Some were suffering from a strangulated hemorrhoid symptoms, necrosis, severe pain and fever. Some had strangulated hemorrhoids with persistent bleeding due to the use of warfarin, which is used in the treatment of coronary insufficiency. Some suffered from hemorrhoids with bleeding, which did not stop for ten days or more, as well as from diseases related to blood, such as a violation of bleeding and severe anemia. Some had polyps of the rectum or lumps in the anus. Patients were generally older, one of them was a 95-year-old patient with hemangiomas in the anus.
Treatments are as follows. The patient was organized by local disinfection, and then in the pathological tissue was injected required dose races the thief polizeiskogo sulfate, containing local anaesthetic. For example, each available node or tumor immediately hardened after application of the solution, and within minutes was soft and allocated liquid, the bleeding stopped, the pain stopped. The amount of the hemorrhoid was reduced to one-fifth or one-seventh of the volume before treatment after 10-30 minutes. Hemorrhoidal site was involved in the anus. Atrofirovany node or tumor or was absorbed, or fall off after 4-8 days. All patients were treated by applying the same procedures, and all without exception were observed the same process.
The treatment of the present invention focused on pathological tissues without damaging normal tissues or physiological structures. Treatment method is very easy, it is cheap, safe and fast run. In addition, the method can be widely applied and has no serious contraindications. For example, the present method has more significant effects than existing surgical techniques, such as Stripping, ligation and suturing of vessels; provides a more significant effect than modern methods of administration of drugs, such as the introduction of tanning substances, the introduction of substances that cause necrosis and sleek injection; gives greater efficiency is, than modern physiotherapeutic methods, such as electrocautery, laser therapy, cryotherapy, microwave therapy, low-frequency therapy, therapy with radiofrequency therapy using electric fields, iontophoresis and therapy with the use of the generator, and even more significantly effective than treatment of PPH (procedure for the deposition and hemorrhoids), which proposed and strongly supported by national and international medical community, in relation to methods of treatment of hemorrhoids, varicose extensions, angiomas and local tumors. In fact, many patients who were treated with the proposed invention by a method previously received surgical treatment by the method of PPH, or other modern methods.
Fig. 2 through 12 show the effect of treatment of patients from 2 to 12.
Figure 2 shows the treatment of peripheral mixed hemorrhoids. On these drawings figa shows local pathological field of a patient with symptoms of necrosis, bleeding, suppuration and high temperature. Figv shows that hemorrhoids dehydrated, Trofimova and is removed in the process of drug administration. Pigs shows that hemorrhoids have been drawn into the anus after 25 minutes after drug administration, and endoscopy showed that the volume of hemorrhoids have shrunk to one-fifth of that of b is La before treatment. Fig.2D shows the effect of treatment after 17 hours after the procedure. File shows a view of the anus through 5 days after the procedure. Fig.2F shows the result of endoscopy 35 days after the procedure.
Figure 3 shows the treatment of mixed hemorrhoids and tumors, dropped out of the anus. Figa shows the pathological area before treatment. Figv shows how the tumor begins to shrink, first 3 minutes after drug administration. Figs shows how the tumor is drawn into the anus after 25 minutes after the procedure. Fig.3D shows how the tumor disappears and hemorrhoids atrophies when the patient tries to push the hemorrhoids. File shows that the hemorrhoids will be automatically drawn into the anus. Fig.3F shows that the pathological tissue falls off after 8 days. Fig.3G shows that the wound has almost healed in 15 days.
Figure 4 shows the treatment of peripheral mixed hemorrhoids, when not stopped bleeding. On these drawings figa shows the pathological area before treatment. Figv shows the injection solution medications for dehydration and Trofimovna. Figs shows the pathological area 10 minutes after the injection. Fig.4D shows the pathological area in 25 minutes after the injection.
Figure 5 shows the procedure for treatment of another peripheral mixed is morroa with symptoms of necrosis. On these drawings figa shows the pathological area before treatment. Figv shows the injection solution medications for dehydration and Trofimovna. Figs shows full medication for 5 minutes. Fig.5D shows how the abnormal tissue undergoes dehydration and Trofimovna through 29 minutes after injection. File shows how atrofirovany hemorrhoids is drawn into the anus after 30 minutes after injection. Fig.5F shows the view through the anoscope through the 31st minute after injection. Fig.5G shows the wound after 11 days after removal of hemorrhoids. Fign shows the anus through 41 days after treatment.
6 shows the treatment of anal dilatation lower anal canal serrated line. In the drawings Figa shows the pathological area before treatment. Figv shows the introduction of the drug. Pigs shows that the solution is completely entered in 7 minutes and a previously processed hemorrhoids atrophied. Fig.6D shows the state after 22 minutes. File shows the state after 25 minutes. Fig.6F shows the state after defecation after 2 days.
Fig.7 shows the treatment process 95 year old woman who suffered from diabetes, hypertension and stroke. The patient was also angioma, which dropped out of the anus. On these drawings Figa shows the pathological area before treatment. Figv shows the t, that the tumor has the form of a tree with foliage, leaves, fruits, stem and roots; the drug is administered in the crown. Figs shows the introduction of drugs in the trunk and roots for dehydration and atrophy of these places and detachment dormant crowns. Fig.7D shows the pathological state of the field in 12 minutes.
Fig shows the procedure of treatment of the patient, male 78 years, who suffered from hypertension and was taking cardiac depressant, anti-hypertensive drugs and warfin a long time. The patient also suffered from tumors, which dropped out of the anus.
On these drawings figa shows the pathological area before treatment. Figv shows the pathological area after the injection. Pigs shows that the tumor atrophied after 15 minutes. Fig.8D shows that rotation of the fabric peeled off after 11 days. File shows prolonged wound through day 41. Fig.8F indicates the state of the anus.
Fig.9 shows the process of treatment 52-year-old patient, who suffered from pancreatic cancer. The patient also suffered from mixed hemorrhoids and polyphem narrowing with symptoms of necrosis, suppuration and unbearable pain. On these drawings figa shows the pathological area before treatment. Figv shows hemorrhoids during drug administration. Pigs shows that the drug is completely entered and the hemorrhoids at operetta. Fig.9D shows that atrofirovany hemorrhoids is drawn into the anus after 20 minutes, the size of the hemorrhoids 1.5 cm in diameter. File shows that after 6 days peeled off the black stuff. Fig.9G shows the condition of the wound after 21 days.
Figure 10 shows the process of treating a 60-year old patient who was suffering from a strangulated hemorrhoids. This patient underwent heart surgery and suffered from angina. It took a long time warfarin and hemorrhoids did not stop bleeding. On these drawings Figa shows the pathological area before treatment. Figv shows the pathological area in 2 minutes after drug administration. Pigs shows that hemorrhoids dehydrated and Trofimova and stopped bleeding after 5 minutes. Fig.10D shows that hemorrhoids have been drawn into the anus after 15 minutes. File shows atrofirovany hemorrhoids in the anus.
11 shows the process of treatment 56-year-old patient, who suffered a recurrence of hemorrhoids. The patient also suffered from hypertension and angina, it is a long time took warfarin. Hemorrhoids fell out after defecation and bleeding. The patient was twice operated over ligation of vessels over the last 4 years. On these drawings Figa shows the pathological area before surgery. Figv shows the pathological area after drug administration. Figs shows obasogie is hydrated and atrofirovany hemorrhoids after 5 minutes. Fig.11D shows that hemorrhoids have been drawn into the anus. File shows the internal without the use of drugs. Fig.11F shows the introduction of additional medications. Fig.11G indicates the state of the anus on day 14.
Fig shows the treatment process 83-year-old patient, who suffered from hypertension and diabetes. The patient is 10 years old it was falling out after defecation (utgivelsene). The patient also suffered from mixed hemorrhoids, external hemorrhoid part on the type of varicose and internal hemorrhoidal part on the type of erosion hemorrhoids. On these drawings figa shows pathological part before treatment. Figv shows the pathological area after drug administration. Figs shows hemorrhoids, drawn into the anus after 14 minutes. Fig.12D shows the view when examining the anoscope. File shows the separated part on day 5. Fig.12F pathological region on the 11th day. Fig.12G shows the abnormal area on the 30th day.
1. Pharmaceutical composition for dehydration, Trofimovna and removal of pathological tissues, including composite polymer inorganic ferrous salt as an active ingredient, as a composite of polymer inorganic ferrous salt selected polymeric ferric sulfate silicate (PFSS), or polyglutamyl silicate chloride (PFSC), or half the phosphate, ferrous sulfate (PPFS).
2. The pharmaceutical composition according to claim 1, where the finished form specified in the pharmaceutical composition is in the form of powder or paste, or powder for injection, or aqueous solution, or composition for injection, liquid or ointment for external use, suppositories, or spray.
3. The pharmaceutical composition according to claim 2, where the specified pharmaceutical composition further comprises one or two anesthetic selected from the group consisting of levobupivacaine, ropivacaine, hydrochloride lidocaine, menthol, methylene blue, procaine and tetracaine.
4. The pharmaceutical composition according to claim 3, where this pharmaceutical composition is a powdered form containing 1-60 wt.% composite polymer inorganic ferrous salt, a sufficient amount of anesthetic required to balance the amount of pharmaceutically acceptable solid filler.
5. The pharmaceutical composition according to claim 3, where this pharmaceutical composition is a powdered form containing 1-60 wt.% composite polymer inorganic ferrous salt, 40-80 wt.% the zeolite powder and the desired balance amount of another pharmaceutically acceptable solid filler.
6. The pharmaceutical composition according to claim 4, where this pharmaceutical composition is a paste containing 1-60 wt.% composite reorganizes the Oh polymer ferrous salt, a sufficient amount of anesthetic required to balance the amount of pharmaceutically acceptable solid filler.
7. The pharmaceutical composition according to claim 3, where this pharmaceutical composition is an aqueous solution containing 0.2 to 60 wt.% composite polymer inorganic ferrous salt, a sufficient amount of anesthetic required to balance the amount of water.
8. The use of the pharmaceutical composition according to any one of claims 1 to 7 for the preparation of a medicinal product for dehydration, atrophy and removal of pathological tissues.
9. The use of the pharmaceutical composition of claim 8 as a medicine for the treatment of hemorrhoids, hemangiomas, varicose veins, tumors, burns, traumatic wounds bleeding and/or the local wounds caused by chemical substances or microorganisms, in the form of powder or paste, or powder for injection, or aqueous solution, or composition for injection, liquid or ointment for external use, suppositories, or spray.